Chikungunya vaccine gets approval in America, you will be stunned to see the symptoms

There is news of a major achievement in the fight against Chikungunya. America has approved Chikungunya vaccine. This is the world’s first vaccine against this disease. The Food and Drug Administration (FDA) has given this information. Let us tell you that recently the FDA had described Chikungunya as an ’emerging global health threat’. This vaccine will be manufactured by Europe’s Valneva company, which has been named Ixchik.

Vaccine will be given to those above 18 years of age

According to the FDA, this vaccine will be given to people above 18 years of age and facing serious risk. The company has conducted vaccine trials on 3,500 people in North America. After giving the vaccine, symptoms like minor headache, fatigue, muscle and joint pain, fever and nausea have been observed in people. Serious reactions also occurred in 1.6 percent of people tested and 2 people had to be hospitalized.

The vaccine is 98 percent effective

According to a report, the vaccine has shown ‘highly protective’ results in the third phase of clinical trials. It says that the vaccine has been 98.9 percent effective 28 days after giving a single dose. Out of 266 people who were vaccinated, 263 people had an immunity reaction. The company making the vaccine has now applied for approval in Europe.

The first case of chikungunya was reported in 1952

The first case of chikungunya was reported in Tanzania in 1952. Its first case in India was reported in 1963. It is also known as break breaking fever. So far, its cases have been reported in more than 110 countries. This disease is spread by a mosquito called Aedes. In the last 15 years, more than 5 million cases of chikungunya have been reported worldwide.

Let us tell you that the symptoms of chikungunya and dengue are similar. Usually its symptoms do not appear for several days, due to which its severity is also high. During this period, the patient develops fever, severe joint pain and red rashes. It is detected only after RT-PCR test. Most of its cases occur in Africa, South East Asia and some parts of America.